Here’s a quick summary of some of the major events related to pharmacy compounding in just this past week or so:
SB 282 was introduced in the Indiana state senate. Another drugmaker-pushed bill that aims to restrict compounding and burden it with additional and unnecessary paperwork. Good news: The senate’s Committee on Health and Provider Services, flooded with public testimony, has delayed a vote on the bill until this coming Wednesday. Part of that flood was courtesy of APC, in fact — we arranged for compounders, including Board Chair Phillip Smyth, to testify at the committee meeting, and yes, we’ll continue to apply the necessary pressure to protect patients from this kind of shenanigans. It's a bit lengthy, but well worth your time to watch.
Strive sued Lilly and Novo. Compounding pharmacy (and APC PFM) Strive Specialties has filed an antitrust lawsuit in Texas against the two big GLP-1 makers, “alleging Lilly and Novo abused their dominance in the GLP‑1 drug market to keep patients from obtaining lower-cost versions of the medications.”
We built a team to fight drugmakers’ bills. Thanks to funds contributed to our Compounding Defense Fund, we have engaged lobbyists in Florida, Indiana, and Colorado where anti-compounding legislation has been introduced, pushed by (and perhaps authored by) pharmaceutical companies. (Read more below in “Cheers for the defense.”)
Our version of the Yalta Conference. As Philip mentioned in his column above, APC this week convened a meeting with pharmacy compounding lobbyists and a wide range of stakeholders: compounding pharmacies, telehealth platform, and other industry partners. The goal was to find our common ground and use it to coordinate and collaborate on a broad legislative, regulatory, and political strategy.